MAPT and Alzheimer disease: As a link has been demonstrated between NFTs and AD symptoms, tau PET tracers are increasingly being used in AD clinical trials, especially those investigating drugs to reduce the tau or Aβ burden (129), such as Aβ monoclonal antibodies.